DNA repair defects in prostate cancer: impact for screening, prognostication and treatment

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Defective DNA damage repair is increasingly recognized as a critical factor in aggressive prostate cancer progression.
• Germline and somatic alterations in DNA repair pathways, especially homologous recombination and mismatch repair, are common in lethal metastatic prostate cancer.

Purpose of the Study:

• To review the relationship between DNA repair defects and prostate cancer.
• To highlight the prevalence of mutations in key DNA repair genes.
• To discuss the association of these defects with clinical outcomes and treatment responses.

Main Methods:

• Review of recent international sequencing efforts and literature.
• Analysis of prevalence data for germline and somatic alterations in DNA repair pathways.
• Examination of existing evidence on the link between DNA repair defects and prostate cancer prognosis and therapy response.

Main Results:

• Alterations in homologous recombination and mismatch repair pathways are prevalent in metastatic prostate cancer.
• BRCA2 gene alterations are particularly common and associated with poor prognosis, though treatment response data is conflicting.
• DNA repair defects contribute to tumor heterogeneity, evolution, and progression.

Conclusions:

• DNA repair defects are significant drivers of aggressive prostate cancer.
• Targeted therapies like PARP inhibitors and platinum-based chemotherapy hold promise for treating this subset of patients.
• Further research is needed to clarify the controversial associations with clinical outcomes and optimize treatment strategies.